A phase I dose escalation study of BMS-690514 in patients with advanced or metastatic solid tumors.

Trial Profile

A phase I dose escalation study of BMS-690514 in patients with advanced or metastatic solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2010

At a glance

  • Drugs BMS 690514 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 May 2010 Planned number of patients changed from 95 to 110 as reported by M.D. Anderson Cancer Center record.
    • 14 Jul 2009 Actual end date (May 2009) and actual number of patients (89) added as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top